{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:43:34Z","timestamp":1771263814450,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>COVID- 19, caused by the coronavirus SARS-CoV- 2, has arisen as a global health epidemic, claiming the lives of millions of people throughout the world. Combating the pandemic has involved developing and approving vaccines and antiviral products. Camostat Mesylate (Camo) is a TMPRSS2 inhibitor that inhibits virus-cell membrane fusion and, thereby, viral multiplication. Significant limitations of using oral Camo include the limited amount of Camo reaching the site of action, lungs, side effects due to distribution to all tissues, and enzymatic breakdown in the gut. This investigation aims to develop self-administrable and patient-compliant extended-release Camo-loaded pegylated nanoliposomes (Camo-pegNLs) for delivering Camo directly to the lungs, thereby enabling faster onset of action and overcoming limitations of oral Camo delivery. We developed the Camo-pegNLs were composed of 1,2-dipalmitoyl-sn-glycerol- 3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycerol- 3-phosphoethanolamine (DOPE-PEG, MW2000) and cholesterol using the ethanol injection technique and syringe pump. The NLs were characterized for their particle size, polydispersity index (PDI), and zeta potential using Malvern Zetasizer. The assay, unentrapped Camo using Vivaspin 500 ultrafilter (10 kDa) and in-vitro release were determined. The Camo content was analyzed using a validated HPLC method. The aerodynamic properties of Camo-pegNLs were determined using a Westech Andersen Cascade Impactor (ACI) at 28.3L\/min and a pneumatic jet nebulizer. The antiviral effect of Camo-pegNLs was assessed in Vero cells expressing TMPRSS2 and infected with SARS-CoV- 2. Camo-pegNLs suspension showed size of 167.50 \u00b1\u20090.90 nm, zeta potential of 0.48 \u00b1\u20090.04 mV, and PDI of 0.07 \u00b1\u20090.01. The quantity of entrapped Camo was found to be 44.86 \u00b1\u20091.35%w\/v, and the drug loading was 27.41 \u00b1\u20090.04%w\/w. The Camo-pegNL- 2 had an extended release of up to 24 h, MMAD of 4.295 \u00b1\u20090.1 \u00b5m, GSD of 1.915 \u00b1\u20090.064, and FPF of 42.01% \u00b1\u20096.90. Camo-pegNLs showed a significant antiviral effect on Vero cells compared to no treatment group (<jats:italic>p<\/jats:italic>\u2009&lt; 0.01). An efficacious nebulized Camo-pegNLs suspension product was successfully developed for direct lung delivery to Camo-pegNLs to treat the SARS-CoV- 2 infection.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>\n          <jats:p>SARS-CoV- 2<\/jats:p>","DOI":"10.1208\/s12249-025-03099-3","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T21:14:14Z","timestamp":1747430054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Formulation and In-Vitro Testing of Nebulized Camostat Mesylate Loaded Nanoliposomes for the Treatment of SARS-CoV- 2 Infection"],"prefix":"10.1208","volume":"26","author":[{"given":"Rama","family":"Kashikar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun Kumar","family":"Kotha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakshya","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudragouda","family":"Channappanavar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-4344","authenticated-orcid":false,"given":"Mahavir Bhupal","family":"Chougule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"6","key":"3099_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3892\/ijmm.2020.4555","volume":"45","author":"AO Docea","year":"2020","unstructured":"Docea AO, Tsatsakis A, Albulescu D, et al. A new threat from an old enemy: re-emergence of coronavirus (Review). Int J Mol Med. 2020;45(6):1631\u201343. https:\/\/doi.org\/10.3892\/ijmm.2020.4555.","journal-title":"Int J Mol Med"},{"issue":"8","key":"3099_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2001017.","journal-title":"N Engl J Med"},{"issue":"10223","key":"3099_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s0140-6736(20)30154-9","volume":"395","author":"JF Chan","year":"2020","unstructured":"Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(20)30154-9.","journal-title":"Lancet"},{"key":"3099_CR4","doi-asserted-by":"publisher","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","volume":"109","author":"HA Rothan","year":"2020","unstructured":"Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https:\/\/doi.org\/10.1016\/j.jaut.2020.102433.","journal-title":"J Autoimmun"},{"issue":"8","key":"3099_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s2213-2600(20)30304-0","volume":"8","author":"E Fan","year":"2020","unstructured":"Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med. 2020;8(8):816\u201321. https:\/\/doi.org\/10.1016\/s2213-2600(20)30304-0.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3099_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/joim.13091","volume":"288","author":"G Pascarella","year":"2020","unstructured":"Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192\u2013206. https:\/\/doi.org\/10.1111\/joim.13091.","journal-title":"J Intern Med"},{"key":"3099_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","volume":"24","author":"MA Shereen","year":"2020","unstructured":"Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91\u20138. https:\/\/doi.org\/10.1016\/j.jare.2020.03.005.","journal-title":"J Adv Res"},{"issue":"1","key":"3099_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3\u201320. https:\/\/doi.org\/10.1038\/s41580-021-00418-x.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3099_CR9","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Hofmann-Winkler H, P\u00f6hlmann S. Priming time: how cellular proteases arm coronavirus spike proteins. Activation of Viruses by Host Proteases; 2018. p. 71\u201398.","DOI":"10.1007\/978-3-319-75474-1_4"},{"issue":"2","key":"3099_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"key":"3099_CR11","unstructured":"Fact sheet for healthcare providers administering vaccine (Vaccination providers). https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=17227&format=pdf. Accessed 19 Jan 2024."},{"key":"3099_CR12","unstructured":"Fact sheet for healthcare providers administering vaccine (vaccination providers). https:\/\/www.fda.gov\/media\/144637\/download. Accessed 8 July 2023."},{"key":"3099_CR13","unstructured":"Us_Fda. Novavax COVID-19 Vaccine, Adjuvanted | FDA; 2023."},{"key":"3099_CR14","doi-asserted-by":"publisher","unstructured":"Kim G, Moon HK, Kim T, et al. Safety evaluation and population pharmacokinetics of camostat mesylate and its major metabolites using a phase I study. Pharmaceutics. 2023;15(9). https:\/\/doi.org\/10.3390\/pharmaceutics15092357.","DOI":"10.3390\/pharmaceutics15092357"},{"key":"3099_CR15","doi-asserted-by":"publisher","unstructured":"Expert consensus on nebulization therapy in pre-hospital and in-hospital emergency care. Ann Transl Med. 2019;7(18):487. https:\/\/doi.org\/10.21037\/atm.2019.09.44.","DOI":"10.21037\/atm.2019.09.44"},{"key":"3099_CR16","doi-asserted-by":"publisher","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2). https:\/\/doi.org\/10.3390\/pharmaceutics9020012.","DOI":"10.3390\/pharmaceutics9020012"},{"issue":"4","key":"3099_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40139-021-00227-z","volume":"9","author":"S Sharma","year":"2021","unstructured":"Sharma S, Parveen R, Chatterji BP. Toxicology of nanoparticles in drug delivery. Curr Pathobiol Rep. 2021;9(4):133\u201344. https:\/\/doi.org\/10.1007\/s40139-021-00227-z.","journal-title":"Curr Pathobiol Rep"},{"key":"3099_CR18","unstructured":"Technology CS. Camostat Mesylate #42819."},{"issue":"3","key":"3099_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1039\/D0SC05064D","volume":"12","author":"T Hempel","year":"2021","unstructured":"Hempel T, Raich L, Olsson S, et al. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat. Chem Sci. 2021;12(3):983\u201392. https:\/\/doi.org\/10.1039\/D0SC05064D.","journal-title":"Chem Sci"},{"issue":"19","key":"3099_CR20","doi-asserted-by":"publisher","first-page":"e0086121","DOI":"10.1128\/jvi.00861-21","volume":"95","author":"G Sun","year":"2021","unstructured":"Sun G, Sui Y, Zhou Y, et al. Structural basis of covalent inhibitory mechanism of TMPRSS2-related serine proteases by camostat. J Virol. 2021;95(19):e0086121. https:\/\/doi.org\/10.1128\/jvi.00861-21.","journal-title":"J Virol."},{"key":"3099_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cherd.2014.09.008","volume":"94","author":"C Charcosset","year":"2015","unstructured":"Charcosset C, Juban A, Valour J-P, Urbaniak S, Fessi H. Preparation of liposomes at large scale using the ethanol injection method: Effect of scale-up and injection devices. Chem Eng Res Des. 2015;94:508\u201315. https:\/\/doi.org\/10.1016\/j.cherd.2014.09.008.","journal-title":"Chem Eng Res Des"},{"key":"3099_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-0716-2954-3_5","volume":"2622","author":"G Du","year":"2023","unstructured":"Du G, Sun X. Ethanol injection method for liposome preparation. Methods Mol Biol. 2023;2622:65\u201370. https:\/\/doi.org\/10.1007\/978-1-0716-2954-3_5.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"3099_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s41598-024-82228-7","volume":"15","author":"A Miatmoko","year":"2025","unstructured":"Miatmoko A, Christy PK, Isnaini A, et al. Characterization and in vitro anticancer study of PEGylated liposome dually loaded with ferulic acid and doxorubicin. Sci Rep. 2025;15(1):1236. https:\/\/doi.org\/10.1038\/s41598-024-82228-7.","journal-title":"Sci Rep"},{"issue":"2","key":"3099_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","volume":"61","author":"SK Lai","year":"2009","unstructured":"Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158\u201371. https:\/\/doi.org\/10.1016\/j.addr.2008.11.002.","journal-title":"Adv Drug Deliv Rev"},{"key":"3099_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","volume":"124","author":"JT Huckaby","year":"2018","unstructured":"Huckaby JT, Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus. Adv Drug Deliv Rev. 2018;124:125\u201339. https:\/\/doi.org\/10.1016\/j.addr.2017.08.010.","journal-title":"Adv Drug Deliv Rev"},{"key":"3099_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","volume":"285","author":"G Osman","year":"2018","unstructured":"Osman G, Rodriguez J, Chan SY, et al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release. 2018;285:35\u201345. https:\/\/doi.org\/10.1016\/j.jconrel.2018.07.001.","journal-title":"J Control Release"},{"key":"3099_CR27","doi-asserted-by":"publisher","unstructured":"Pajor-\u015awierzy A, Sta\u015bko D, Paw\u0142owski R, Mordarski G, Kamyshny A, Szczepanowicz K. Polydispersity vs. monodispersity. How the properties of Ni-Ag core-shell nanoparticles affect the conductivity of ink coatings. Materials (Basel). 2021;14(9). https:\/\/doi.org\/10.3390\/ma14092304.","DOI":"10.3390\/ma14092304"},{"issue":"9","key":"3099_CR28","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1021\/nn404501g","volume":"7","author":"K Park","year":"2013","unstructured":"Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano. 2013;7(9):7442\u20137. https:\/\/doi.org\/10.1021\/nn404501g.","journal-title":"ACS Nano"},{"issue":"7","key":"3099_CR29","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1021\/acs.biomac.8b00589","volume":"19","author":"L Palanikumar","year":"2018","unstructured":"Palanikumar L, Choi ES, Oh JY, et al. Importance of encapsulation stability of nanocarriers with high drug loading capacity for increasing in vivo therapeutic efficacy. Biomacromol. 2018;19(7):3030\u20139. https:\/\/doi.org\/10.1021\/acs.biomac.8b00589.","journal-title":"Biomacromol"},{"key":"3099_CR30","doi-asserted-by":"publisher","first-page":"105810","DOI":"10.1016\/j.jddst.2024.105810","volume":"98","author":"R Kashikar","year":"2024","unstructured":"Kashikar R, Kotha AK, Shrestha R, Channappanavar R, Chougule MB. Design of experiments using box behnken design in the development, characterization, mathematical modeling, and evaluation of lung targeted nebulized antiviral camostat mesylate loaded pegylated nanosuspension product. J Drug Deliv Sci Technol. 2024;98:105810. https:\/\/doi.org\/10.1016\/j.jddst.2024.105810.","journal-title":"J Drug Deliv Sci Technol."},{"key":"3099_CR31","unstructured":"Kotha AK, Vinjamuri BP, Chougule MB. Formulation and evaluation of doxorubicin hcl nanoliposomes by ethanol injection method. https:\/\/egrove.olemiss.edu\/pharm_annual_posters\/16\/. Accessed 23 Feb 2024."},{"key":"3099_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejpb.2021.05.021","volume":"166","author":"Z Li","year":"2021","unstructured":"Li Z, Perkins W, Cipolla D. Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow\u00ae Technology. Eur J Pharm Biopharm. 2021;166:10\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2021.05.021.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3099_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1208\/s12249-013-9988-3","volume":"14","author":"SR Youngren","year":"2013","unstructured":"Youngren SR, Mulik R, Jun B, Hoffmann PR, Morris KR, Chougule MB. Freeze-dried targeted mannosylated selenium-loaded nanoliposomes: development and evaluation. AAPS PharmSciTech. 2013;14(3):1012\u201324. https:\/\/doi.org\/10.1208\/s12249-013-9988-3.","journal-title":"AAPS PharmSciTech"},{"key":"3099_CR34","unstructured":"Hanes J, Chan KWY, McMahon MT, Yang M, Yu T. inventor; Lipid-based drug carriers for rapid penetration through mucus linings. 2018."},{"key":"3099_CR35","doi-asserted-by":"crossref","unstructured":"Mujun Zhang TS, Lei Y, Chen W, Mu S, Pan Y, Zhao H. Developing and validating an HPLC method for related substance of camostat mesilate in bulk. 2022.","DOI":"10.34297\/AJBSR.2022.15.002085"},{"key":"3099_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1155\/2016\/2861915","volume":"2016","author":"K Li","year":"2016","unstructured":"Li K, Zhang H, Gao L, et al. Preparation and characterization of baicalein-loaded nanoliposomes for antitumor therapy. J Nanomaterials. 2016;2016:12. https:\/\/doi.org\/10.1155\/2016\/2861915.","journal-title":"J Nanomaterials"},{"issue":"4","key":"3099_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4103\/0970-2113.159559","volume":"32","author":"JS Patil","year":"2015","unstructured":"Patil JS, Devi VK, Devi K, Sarasija S. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis. Lung India. 2015;32(4):331\u20138. https:\/\/doi.org\/10.4103\/0970-2113.159559.","journal-title":"Lung India"},{"issue":"8","key":"3099_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/pharmaceutics12080732","volume":"12","author":"J Weng","year":"2020","unstructured":"Weng J, Tong HHY, Chow SF. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. Pharmaceutics. 2020;12(8):732. https:\/\/doi.org\/10.3390\/pharmaceutics12080732.","journal-title":"Pharmaceutics"},{"key":"3099_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejps.2014.10.002","volume":"66","author":"F Xie","year":"2015","unstructured":"Xie F, Ji S, Cheng Z. In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example. Eur J Pharm Sci. 2015;66:163\u201372. https:\/\/doi.org\/10.1016\/j.ejps.2014.10.002.","journal-title":"Eur J Pharm Sci"},{"key":"3099_CR40","unstructured":"Bhandari P, Malik A, Sapra A. Vital sign assessment. Text. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553213\/. Accessed 24 Feb 2024."},{"issue":"2","key":"3099_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.idc.2022.02.005","volume":"36","author":"TD Bell","year":"2022","unstructured":"Bell TD. COVID-19 in the critically Ill patient. Infect Dis Clin North Am. 2022;36(2):365\u201377. https:\/\/doi.org\/10.1016\/j.idc.2022.02.005.","journal-title":"Infect Dis Clin North Am"},{"key":"3099_CR42","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.ijpx.2021.100074","volume":"3","author":"G Shadambikar","year":"2021","unstructured":"Shadambikar G, Marathe S, Ji N, et al. Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology. Int J Pharm X. 2021;3:100074. https:\/\/doi.org\/10.1016\/j.ijpx.2021.100074.","journal-title":"Int J Pharm X"},{"key":"3099_CR43","doi-asserted-by":"publisher","unstructured":"Raffaelli F, Tanzarella ES, De Pascale G, Tumbarello M. Invasive respiratory fungal infections in COVID-19 critically ill patients. J Fungi (Basel). 2022;8(4). https:\/\/doi.org\/10.3390\/jof8040415.","DOI":"10.3390\/jof8040415"},{"issue":"Pt A","key":"3099_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.09.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"3099_CR45","unstructured":"Us_Fda. Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry | FDA; 2023."},{"key":"3099_CR46","unstructured":"Us_Fda. Reviewer Guidance, Validation of Chromatographic Methods | FDA; 2023."},{"issue":"8","key":"3099_CR47","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4155\/tde.13.71","volume":"4","author":"D Cipolla","year":"2013","unstructured":"Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther Deliv. 2013;4(8):1047\u201372. https:\/\/doi.org\/10.4155\/tde.13.71.","journal-title":"Ther Deliv"},{"key":"3099_CR48","doi-asserted-by":"publisher","unstructured":"Guimar\u00e3es D, Noro J, Loureiro A, et al. Increased encapsulation efficiency of methotrexate in liposomes for rheumatoid arthritis therapy. Biomedicines. 2020;8(12). https:\/\/doi.org\/10.3390\/biomedicines8120630.","DOI":"10.3390\/biomedicines8120630"},{"issue":"1","key":"3099_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jconrel.2006.03.014","volume":"113","author":"Y-Y Huang","year":"2006","unstructured":"Huang Y-Y, Wang C-H. Pulmonary delivery of insulin by liposomal carriers. J Control Release. 2006;113(1):9\u201314. https:\/\/doi.org\/10.1016\/j.jconrel.2006.03.014.","journal-title":"J Control Release"},{"key":"3099_CR50","doi-asserted-by":"publisher","unstructured":"Khaleseh F, HemmatiAzandaryani A, FathianKolahkaj F, Khazaei M, Derakhshandeh K. Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. IET Nanobiotechnol. 2021;15(3):257\u201365. https:\/\/doi.org\/10.1049\/nbt2.12012. Accessed 26 Feb 2024.","DOI":"10.1049\/nbt2.12012"},{"key":"3099_CR51","unstructured":"DrugBank. Epirubicin. https:\/\/go.drugbank.com\/drugs\/DB00445."},{"key":"3099_CR52","doi-asserted-by":"publisher","unstructured":"Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022;14(3). https:\/\/doi.org\/10.3390\/pharmaceutics14030543.","DOI":"10.3390\/pharmaceutics14030543"},{"key":"3099_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2147\/ijn.S39025","volume":"8","author":"PR Karn","year":"2013","unstructured":"Karn PR, Cho W, Park HJ, Park JS, Hwang SJ. Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham method. Int J Nanomedicine. 2013;8:365\u201377. https:\/\/doi.org\/10.2147\/ijn.S39025.","journal-title":"Int J Nanomedicine"},{"key":"3099_CR54","unstructured":"Us_Fda. Center for Drug Evaluation and Research | CDER | FDA; 2023."},{"issue":"5","key":"3099_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/02652048.2013.879932","volume":"31","author":"J Wolfram","year":"2014","unstructured":"Wolfram J, Suri K, Huang Y, et al. Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. J Microencapsul. 2014;31(5):501\u20137. https:\/\/doi.org\/10.3109\/02652048.2013.879932.","journal-title":"J Microencapsul."},{"issue":"6","key":"3099_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2159-8290.Cd-20-0451","volume":"10","author":"KH Stopsack","year":"2020","unstructured":"Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10(6):779\u201382. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0451.","journal-title":"Cancer Discov"},{"key":"3099_CR57","doi-asserted-by":"publisher","first-page":"118603","DOI":"10.1016\/j.ijpharm.2019.118603","volume":"569","author":"D Van Haute","year":"2019","unstructured":"Van Haute D, Jiang W, Mudalige T. Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation. Int J Pharm. 2019;569:118603. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118603.","journal-title":"Int J Pharm"},{"key":"3099_CR58","doi-asserted-by":"publisher","unstructured":"Weng J, Tong HHY, Chow SF. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. Pharmaceutics. 2020;12(8). https:\/\/doi.org\/10.3390\/pharmaceutics12080732.","DOI":"10.3390\/pharmaceutics12080732"},{"issue":"14","key":"3099_CR59","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","volume":"16","author":"R Vartak","year":"2021","unstructured":"Vartak R, Patil SM, Saraswat A, Patki M, Kunda NK, Patel K. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine (Lond). 2021;16(14):1187\u2013202. https:\/\/doi.org\/10.2217\/nnm-2020-0475.","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"3099_CR60","doi-asserted-by":"publisher","first-page":"16803","DOI":"10.1038\/s41598-017-16791-7","volume":"7","author":"RR Joseph","year":"2017","unstructured":"Joseph RR, Tan DWN, Ramon MRM, et al. Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab. Sci Rep. 2017;7(1):16803. https:\/\/doi.org\/10.1038\/s41598-017-16791-7.","journal-title":"Sci Rep."},{"key":"3099_CR61","doi-asserted-by":"publisher","first-page":"105026","DOI":"10.1016\/j.ejps.2019.105026","volume":"138","author":"IY Wu","year":"2019","unstructured":"Wu IY, Bala S, \u0160kalko-Basnet N, di Cagno MP. Interpreting non-linear drug diffusion data: Utilizing Korsmeyer-Peppas model to study drug release from liposomes. Eur J Pharm Sci. 2019;138:105026. https:\/\/doi.org\/10.1016\/j.ejps.2019.105026.","journal-title":"Eur J Pharm Sci"},{"key":"3099_CR62","doi-asserted-by":"crossref","unstructured":"5 - Mathematical models of drug release. In: Bruschi ML, editor. Strategies to Modify the Drug Release from Pharmaceutical Systems. Woodhead Publishing; 2015. p. 63-86.","DOI":"10.1016\/B978-0-08-100092-2.00005-9"},{"issue":"8","key":"3099_CR63","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","volume":"11","author":"Y Guo","year":"2021","unstructured":"Guo Y, Bera H, Shi C, Zhang L, Cun D, Yang M. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm Sin B. 2021;11(8):2565\u201384. https:\/\/doi.org\/10.1016\/j.apsb.2021.05.015.","journal-title":"Acta Pharm Sin B"},{"key":"3099_CR64","doi-asserted-by":"crossref","unstructured":"Mishra B, Singh J. Novel drug delivery systems and significance in respiratory diseases. In: Targeting chronic inflammatory lung diseases using advanced drug delivery systems. 2020. p. 57\u201395.","DOI":"10.1016\/B978-0-12-820658-4.00004-2"},{"issue":"1","key":"3099_CR65","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1208\/s12249-014-0210-z","volume":"16","author":"P Sheth","year":"2015","unstructured":"Sheth P, Stein SW, Myrdal PB. Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers. AAPS PharmSciTech. 2015;16(1):192\u2013201. https:\/\/doi.org\/10.1208\/s12249-014-0210-z.","journal-title":"AAPS PharmSciTech"},{"key":"3099_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.addr.2020.06.023","volume":"167","author":"SP Newman","year":"2020","unstructured":"Newman SP, Chan H-K. In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation. Adv Drug Deliv Rev. 2020;167:135\u201347. https:\/\/doi.org\/10.1016\/j.addr.2020.06.023.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3099_CR67","doi-asserted-by":"publisher","first-page":"257","DOI":"10.15171\/apb.2016.035","volume":"6","author":"S Momeni","year":"2016","unstructured":"Momeni S, Nokhodchi A, Ghanbarzadeh S, Hamishehkar H. The Effect of spacer morphology on the aerosolization performance of metered-dose inhalers. Adv Pharm Bull. 2016;6(2):257\u201360. https:\/\/doi.org\/10.15171\/apb.2016.035.","journal-title":"Adv Pharm Bull"},{"key":"3099_CR68","doi-asserted-by":"publisher","unstructured":"Darquenne C. Deposition Mechanisms. review-article. 2020.\u00a0https:\/\/doi.org\/10.1089\/jamp.2020.29029.cd. Accessed 22 Dec 2023.","DOI":"10.1089\/jamp.2020.29029.cd"},{"key":"3099_CR69","doi-asserted-by":"crossref","unstructured":"Papastefanou C. Chapter 11 - Radioactive Aerosol Analysis. In: L\u2019Annunziata MF, editor. Handbook of Radioactivity Analysis, 3rd edn. Academic Press; 2012. p. 727\u201367.","DOI":"10.1016\/B978-0-12-384873-4.00011-6"},{"key":"3099_CR70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.21065\/19204159.3.165","volume":"2","author":"M Khan","year":"2011","unstructured":"Khan M, Qureshi M, Nazir T, Ur-Rahman N, Khan M. Effect of coating material on the aerodynamic particle size distribution (PSD) of oxis Turbohaler\u00ae using mixing inlet with an Andersen Cascade Impactor (ACI). J Appl Pharm. 2011;2:165\u201378. https:\/\/doi.org\/10.21065\/19204159.3.165. (ISSN 19204159).","journal-title":"J Appl Pharm"},{"issue":"3","key":"3099_CR71","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/jamp.2008.0686","volume":"21","author":"Z Li","year":"2008","unstructured":"Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv. 2008;21(3):245\u201354. https:\/\/doi.org\/10.1089\/jamp.2008.0686.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"3099_CR72","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.2147\/dddt.S146111","volume":"14","author":"O Khan","year":"2020","unstructured":"Khan O, Chaudary N. The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults. Drug Des Devel Ther. 2020;14:2287\u201394. https:\/\/doi.org\/10.2147\/dddt.S146111.","journal-title":"Drug Des Devel Ther"},{"key":"3099_CR73","doi-asserted-by":"publisher","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64(6). https:\/\/doi.org\/10.1128\/aac.00754-20.","DOI":"10.1128\/aac.00754-20"},{"issue":"23","key":"3099_CR74","doi-asserted-by":"publisher","first-page":"12552","DOI":"10.1128\/jvi.01890-13","volume":"87","author":"K Shirato","year":"2013","unstructured":"Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552\u201361. https:\/\/doi.org\/10.1128\/jvi.01890-13.","journal-title":"J Virol"},{"issue":"12","key":"3099_CR75","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/jvi.00094-12","volume":"86","author":"M Kawase","year":"2012","unstructured":"Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86(12):6537\u201345. https:\/\/doi.org\/10.1128\/jvi.00094-12.","journal-title":"J Virol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03099-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03099-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03099-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:46:28Z","timestamp":1751906788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03099-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":75,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3099"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03099-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project does not include any human studies. Therefore, ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"There were no human studies were used. Therefore, consent for publication is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors disclose that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"139"}}